Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-01-26
2010-11-16
Haddad, Maher M (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S387900, C435S326000, C435S810000
Reexamination Certificate
active
07833726
ABSTRACT:
The subject of the present invention is to provide a useful antibody for measuring ADAMTS13 activity, in particular, a monoclonal antibody and a method for measuring ADAMTS13 activity. Further, another subject of the present invention also is to provide a monoclonal antibody which has specific reactivity to an antigenic determinant site produced by reacting ADAMTS13 with VWF that is a substrate or a partial peptide of VWF that is a potential substrate, but has no specific reactivity to the complete VWF molecule, and a use of the antibody of interest. Those subjects were achieved by succeeding in obtaining a monoclonal antibody (anti-N-10 monoclonal antibody) which has specific reactivity to a cleavage site that is cleavable by ADAMTS13 in the partial peptide of VWF, and further by finding a method for measuring ADAMTS13 activity using the monoclonal antibody of interest.
REFERENCES:
patent: 4281061 (1981-07-01), Zuk et al.
patent: 7112666 (2006-09-01), Soejima et al.
patent: 2005/0051428 (2005-03-01), Gabriel
patent: 2007/0065895 (2007-03-01), Miyata et al.
patent: WO 2004/035778 (2004-04-01), None
patent: WO 2005/008241 (2005-01-01), None
Dent et al. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc. Nati. Acad. Sci. USA vol. 87, pp. 6306-6310, Aug. 1990.
Mort et al. The use of cleavage site specific antibodies to delineate protein processing and breakdown pathways. Mol Pathol. Feb. 1999;52(1):11-8.
Kato, Seiji, et al., “Monoclonal Antibodies to a VWF-A2 Decapeptide with the C-Terminal Residue Tyr 1605, Generated by ADAMTS13 Cleavage, Develop a Highly Sensitive ELISA for Its Activity and Characterize Upsawh-Schulman Syndrome,” Blood, 2005, 106: Abstract 2643.
Kato, Seiji, et al., “Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity,” Transfusion, Aug. 2006, 46:1444-1452.
Kokame, Koichi, et al., “VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13,” Blood. Jan. 15, 2004, 103(2):607-612.
Zhou, Wenhua and Tsai, Han-Mou, “An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations,” Thromb Haemost, 2004, 91:806-11.
Furlan, “Von Willebrand Factor—Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic-Uremic Syndrome” New Engl. J. of Medicine, vol. 339, No. 22, pp. 1578-1564 (1998).
Tsai et al. “Antibodies to Von Willebrand Factor—Cleaving Protease in Acute Thrombotic Thrombocytopenic Purpura” New Engl. J. of Medicine, vol. 339, No. 22, pp. 1585-1594.
Kinoshita et al, “Upshaw—Schulman Syndrome Revisited: A Concept of Congenital Thrombotic Thrombocytopenic Purpura” International Journal of Hematology, vol. 74, pp. 101-108 (2001).
Soejima et al. “A Novel Human Metalloprotease Synthesized in the Liver and Secreted into the Blood: Possibly, the von Willebrand Factor-Cleaving Protease?” The Journal of Biochemistry, vol. 130, No. 4, pp. 475-480 (2001).
Zheng et al. “Structure of von Willebrand Factor-cleaving Protease: (AAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura” The Journal of Biological Chemistry, vol. 276, No. 44, pp. 41059-41063.
Kokame et al. “VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13” Blood, vol. 103 No. 2, Jan. 15, 2004.
Whitelock et al. “ADAMTS-13 activity in plasma is rapidly measured by a new ELISA method that uses recombinant VWF-A2 domain as substrate” Journal of Thrombosis and Haemostasis, vol. 2; 465-491 (2004).
Zhou et al. “An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations” Thrombosis and Haemostasis, vol. 91, No. 4, pp. 806-811 (2004).
Japanese Journal of Thrombosis and Hemostasis vol. 15 (2004) English Translation.
Ooumi, Shinobu. “Cell technology Separate Volume Jikken Protocol Series New Edition Ant-peptide Kotai Jikken Protocol—Idenshi Sanbutsu no Dotei kara Tanpakushitsu Kono Kaiseiki made—”, Shujunsha Co., Ltd., pp. 130-143 (2004) English Translation.
Fujimura Yoshihiro
Hiura Hisahide
Kato Seiji
Matsumoto Masanori
Alfresa Pharma Corporation
Haddad Maher M
JHK Law
Kim Joseph Hyosuk
LandOfFree
Antibody for assaying ADAMTS13 activity and method for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody for assaying ADAMTS13 activity and method for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody for assaying ADAMTS13 activity and method for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4190382